1. Multidrug resistance in glioblastoma stem-like cells: Role of the hypoxic microenvironment and adenosine signaling
   Daniel Uribe et al, 2017, Molecular Aspects of Medicine CrossRef
2. Targeting Glioblastoma Stem Cells to Overcome Chemoresistance: An Overview of Current Therapeutic Strategies
   Hyunkoo Kang et al, 2022, Biomedicines CrossRef
3. Silencing thelivingene enhances the cytotoxic effects of anticancer drugs on colon cancer cells
   Bo Young Oh et al, 2016, Annals of Surgical Treatment and Research CrossRef
4. Role of multidrug resistance in glioblastoma chemoresistance: Focus on ABC transporters
   Mohammed Ahmed et al, 2021, Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies CrossRef
5. Silencing Livin induces apoptotic and autophagic cell death, increasing chemotherapeutic sensitivity to cisplatin of renal carcinoma cells
   Zhiyang Wang et al, 2016, Tumor Biology CrossRef
6. Small interfering RNA (siRNA) to target genes and molecular pathways in glioblastoma therapy: Current status with an emphasis on delivery systems
   Sepideh Mirzaei et al, 2021, Life Sciences CrossRef
7. The Interaction between DNMT1 and High‐Mannose CD133 Maintains the Slow‐Cycling State and Tumorigenic Potential of Glioma Stem Cell
   Yuanyan Wei et al, 2022, Advanced Science CrossRef
8. Difference in the Inhibitory Effect of Temozolomide on TJ905 Glioma Cells and Stem Cells
   Feng Jin et al, 2017, Frontiers in Neurology CrossRef
9. Targeting Gliomas: Can a New Alkylating Hybrid Compound Make a Difference?
   Rui Pinheiro et al, 2017, ACS Chemical Neuroscience CrossRef
10. Prognostic significance of mutant IDH1, CD133, and β-catenin immunohistochemical expression in glioblastoma multiforme
    Azza Abdel-Aziz et al, 2018, Egyptian Journal of Pathology CrossRef
11. A2B Adenosine Receptor Enhances Chemoresistance of Glioblastoma Stem-Like Cells under Hypoxia: New Insights into MRP3 Transporter Function
    José-Dellis Rocha et al, 2022, International Journal of Molecular Sciences CrossRef
12. Therapeutic Perspective of Temozolomide Resistance in Glioblastoma Treatment
    Qin Xia et al, 2021, Cancer Investigation CrossRef
13. CYLD downregulates Livin and synergistically improves gemcitabine chemosensitivity and decreases migratory/invasive potential in bladder cancer: the effect is autophagy-associated
    Lei Yin et al, 2016, Tumor Biology CrossRef
14. Active targeting co-delivery of therapeutic Sur siRNA and an antineoplastic drug via epidermal growth factor receptor-mediated magnetic nanoparticles for synergistic programmed cell death in glioblastoma stem cells
    Xueqin Wang et al, 2020, Materials Chemistry Frontiers CrossRef
15. A New Platinum-Based Prodrug Candidate for Chemotherapy and Its Synergistic Effect With Hadrontherapy: Novel Strategy to Treat Glioblastoma
    Beatrice Ferrari et al, 2021, Frontiers in Neuroscience CrossRef
16. Nanobodies targeting ABCC3 for immunotargeted applications in glioblastoma
    Eduardo Ruiz-López et al, 2022, Scientific Reports CrossRef